Financials in GBp. Standardized financial statements.
A compact view of how Allergy Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £55.04M | £55.20M | £59.59M | £72.77M | £84.33M | £78.20M | £73.72M | £68.35M | £64.14M | £48.51M |
| Revenue Growth? | -0.3% | -7.4% | -18.1% | -13.7% | +7.8% | +6.1% | +7.9% | +6.6% | +32.2% | 0.0% |
| Cost of Revenue? | £29.91M | £25.46M | £26.90M | £23.81M | £22.53M | £20.69M | £18.38M | £17.01M | £16.77M | £14.07M |
| Gross Profit? | £25.13M | £29.74M | £32.69M | £48.95M | £61.80M | £57.51M | £55.34M | £51.33M | £47.37M | £34.44M |
| Gross Margin? | +45.7% | +53.9% | +54.9% | +67.3% | +73.3% | +73.5% | +75.1% | +75.1% | +73.9% | +71.0% |
| Operating Expenses? | £54.63M | £64.99M | £72.90M | £61.95M | £59.16M | £53.06M | £51.12M | £58.25M | £49.40M | £46.52M |
| Operating Income? | -£29.50M | -£35.26M | -£34.85M | -£13.00M | £4.03M | £4.46M | -£1.84M | -£6.70M | -£1.98M | -£12.12M |
| EBITDA? | -£29.43M | -£30.74M | -£36.24M | -£8.69M | £7.61M | £11.69M | £5.80M | -£4.56M | -£291,000 | -£10.11M |
| Income Before Tax | -£40.44M | -£39.17M | -£42.62M | -£13.40M | £3.66M | £7.44M | £4.29M | -£6.90M | -£1.97M | -£12.06M |
| Income Tax Expense | -£312,000 | £1.05M | £1.30M | £1.12M | £771,000 | £379,000 | £826,000 | £637,000 | £511,000 | £1.01M |
| Net Income? | -£40.13M | -£40.22M | -£43.07M | -£13.78M | £2.89M | £7.06M | £3.47M | -£7.53M | -£2.48M | -£13.07M |
| EPS? | £-0.01 | £-0.01 | £-0.06 | £-0.02 | £0.00 | £0.01 | £0.01 | £-0.01 | £-0.00 | £-0.02 |
| Diluted EPS? | £-0.01 | £-0.01 | £-0.06 | £-0.02 | £0.00 | £0.01 | £0.01 | £-0.01 | £-0.00 | £-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality